ALLAKOS INC (ALLK)
US01671P1003 - Common Stock
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
ALLK stock results show that Allakos missed analyst estimates for earnings per share the fourth quarter of 2023.
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ:ALLK) just reported results for the fourth quarter of 2023.Alla...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
Commit To Buy Allakos At $1, Earn 17.9% Annualized Using Options
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast...
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK). Such investors are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK). Such investors are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK). Such investors are...
Allakos stock falls as analysts downgrade (NASDAQ:ALLK)
Allakos (ALLK) stock faced downgrades as Wall Street reacted to Phase 2 setbacks for its lead asset lirentelimab that led to massive layoffs. Read more here.
Why Is Allakos (ALLK) Stock Down 57% Today?
Allakos stock is falling hard on Tuesday as investors in ALLK react to two of the company's Phase 2 clinical trials failing.
Allakos crashes on restructuring plans (NASDAQ:ALLK)
Allakos (ALLK) stock plummeted 61% after announcing plans to cut its workforce by 50% and focus on specific programs to extend its cash runway. Read more here.
Allakos Announces a Restructuring to Focus on Development of AK006
Allakos Announces a Restructuring to Focus on Development of AK006
Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single...
Commit To Purchase Allakos At $2.50, Earn 194.7% Annualized Using Options
Allakos files to sell up to $250M worth of its common stock (NASDAQ:ALLK)
Allakos filed a prospectus for the sale of its common shares, totaling up to $250M.
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday morning!
Allokos stock jumps 16% as JMP starts coverage at market outperform (ALLK)
JMP initiates coverage of Allakos (ALLK) with a market outperform rating, citing the market potential of its lead drug lirentelimab.
Why Shares of Allakos Are Up Wednesday
The stock is bouncing back from a recent 52-week low.